載入...
Clinical Development of Immune Checkpoint Inhibitors
Recent progress in cancer immunotherapy has been remarkable. Most striking are the clinical development and approval of immunomodulators, also known as immune checkpoint inhibitors. These monoclonal antibodies (mAb) are directed to immune checkpoint molecules, which are expressed on immune cells and...
Na minha lista:
| 發表在: | Biomed Res Int |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi Publishing Corporation
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486755/ https://ncbi.nlm.nih.gov/pubmed/26161407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/605478 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|